Medtronic wins CE Mark approval in the European Union for its Attain Performa Quadripolar leads and begins product launch in Europe. Medtronic (NYSE:MDT), the world’s largest pure-play medical device company, won European regulatory approval for its Attain Performa cardiac lead portfolio. The new product is designed to be paired with Medtronic’s Viva/Brava cardiac resynchronization therapy defibrillators, already on the market in Europe, to offer doctors more variation with electrode placement and pacing configuration. The Attain Performa product has 3 different lead configurations to account for different body shapes. “Our new quadripolar leads were designed with advancements that help physicians customize care for their heart failure patients so they receive the optimal therapy for their condition,” said David Steinhaus, medical director of Medtronic’s cardiac management division.
